Research Progress on Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation -Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 270-275, 2017.
Article
de Zh
| WPRIM
| ID: wpr-311554
Bibliothèque responsable:
WPRO
ABSTRACT
Thrombocytopenia is a major complication following allogeneic stem cell transplantation(allo-HSCT). Overall survival(OS) and disease-free survival(DFS) of patients with thrombocytopenia were lower than those without thrombocytopenia. Lower platelet counts before conditioning, graft-versus-host disease(GVHD) and cytomegalovirus(CMV) infection are adverse factors for the patiens with thrombocytopenia. Bone marrow microenvironment may be involved in the pathogenesis. Thrombopoietin(TPO) and mesenchymal stem cells can improve the platelet counts. In this review the definition, prognosis, pathogenesis and potential therapy for thrombocytopenia after allo-HSCT are summarized.
Texte intégral:
1
Indice:
WPRIM
Type d'étude:
Prognostic_studies
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2017
Type:
Article